SymBiosis and Susquehanna International Group were among a consortium of new and existing backers that supplied $90m in series D financing to Finch Therapeutics.

US-based microbiome therapeutics developer Finch Therapeutics obtained $90m in series D capital on Thursday from investors including medical services provider SymBiosis and quantitative trading firm Susquehanna International Group (SIG).

Baupost Group, Humboldt Fund, MSD Capital, MSD Partners, Octave Group, OMX Ventures, Avenir Growth Capital, OCV Partners, Shumway Capital, Trans-Pacific Technology Fund (TPTF) and Willett Advisors also took part in the transaction.

Finch is developing drugs that restore the microbiome to treat conditions with a serious unmet medical need. Its pipeline…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn